Life Sciences industry veterans with unique real-world data assets
Our unique real world data assets combined with our industry-leading research team are delivering rich, deep data, innovative research, and actionable real-world evidence solutions.
Linked data: the new research standard
While administrative claims data continues to be a trusted workhorse, new linkages to deep, clinical data give traditional real-world data a much-needed boost in horsepower. Claims data linked to electronic health record (EHR) data provides the best of all worlds: deep, rich clinical insights documented in the patient record, linked to detailed information about all costs and services found in claims data.
As one of the largest providers of deidentified ambulatory EHR data that is captured and curated directly from our own point of care systems, we provide flexible linked data solutions supporting multiple claims data providers and linking technologies. Veradigm offers both off-the-shelf and custom linked data solutions that meet your research needs.
Industry veterans driving innovative solutions
Veradigm’s research team is well-regarded throughout the industry, with decades of real-world evidence generation experience from a variety of backgrounds. When our expertise is combined with Veradigm’s linked data assets and point-of-care platforms we are able to drive new, innovative solutions. Take a look at a few of our notable case studies below to see how our data and expertise have combined to delight our clients and advance scientific knowledge.
What can we do for you?
Notable case studies
Identifying and addressing gaps in care
In a study conducted by scientists at Eli Lilly and Veradigm,1 unstructured qualitative provider notes recorded in electronic health records (EHRs) during visits with patients with atopic dermatitis (AD) were shown to rarely to document AD burden on daily functioning and quality of life.
The study demonstrates how combining defined data from EHR structured fields with NLP-extracted information from provider notes captured in unstructured fields offers potential to broaden understanding of AD impact and management.
Retrospective studies
This retrospective cohort study, conducted by researchers from AstraZeneca and Veradigm, used data sourced from a nationwide, electronic health record platform, linked to transactional administrative claims.2
The study provides the first comprehensive evaluation of blood eosinophil count, healthcare utilization, and cost as reflected in current clinical practice across the United States.
Safety and effectiveness studies
In a study conducted by Seqirus and Veradigm and published in Clinical Infectious Diseases,3 individuals four years and older who were vaccinated with cell culture-derived inactivated quadrivalent influenza vaccine (ccIIV4) had significantly fewer influenza-related medical encounters compared with individuals vaccinated with egg-derived inactivated quadrivalent influenza vaccines (eIIV4) during the 2018-19 flu season in the United States.
Study findings “provide further evidence supporting [cell-derived] ccIIV4 as a potentially more effective public health measure against influenza than an egg-derived equivalent.”
Clinical characteristics & healthcare resource use
Early real-world use of erenumab was associated with high adherence and reductions in previously used acute and preventive medications, according to a study conducted by investigators at Amgen and Veradigm and published in Cephalalgia Reports.4
To date, the study is the largest to describe characteristics and treatment patterns of patients who initiated erenumab in US routine clinical practice.
1. Pierce EJ, Boytsov NN, Vasey JJ, et al. A qualitative analysis of provider notes of atopic dermatitis-related visits using natural language processing methods. Dermatol Ther (Heidelb) 30 May 2021; https://doi.org/10.1007/s13555-021-00553-5
2. Trudo F, Kallenbach L, Vasey J, et al. Clinical and economic burden of eosinophilic COPD in a large retrospective US cohort. Int J Chronic Ob Pulmonary Dis 2019:14:2625-2637. doi:10.2147COPD.S220009.
3. Boikos C, Fischer L, O’Brien D, et al. Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States. Clin Infect Dis 2021;ciaa1944. https://pubmed.ncbi.nlm.nih.gov/33400775/
4. Bogdanov A, Chia V, Bensink M, et al. Early use of erenumab in US real world practice. Cephalalgia Rep 31 May 2021;4. https://doi.org/10.1177/25158163211020419